MedTrace Logo

DNA Methylation and Gene Expression in Qataris With Type 2 Diabetes

NCT02021695 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 249

Last updated 2022-01-27

No results posted yet for this study

Summary

With the assessment of the healthy vs. diabetic and pre-diabetic Qatari population the investigators intend to measure the changes in DNA methylation and gene expression in blood monocytes and lymphocytes attributed to diabetes, and to evaluate whether theses changes are persistent or can be reversed by improving diabetes control.

Conditions

Sponsors & Collaborators

  • Hamad Medical Corporation

    collaborator INDUSTRY

  • Weill Cornell Medical College in Qatar

    collaborator OTHER

  • Weill Medical College of Cornell University

    lead OTHER

Principal Investigators

  • Charbel Abi Khalil, MD · Weill Cornell Medical College in Qatar

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Qatar

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02021695 on ClinicalTrials.gov